Universal Health Services Inc. UHS

NYSE; healthcare; SIC 8062, Services-General Medical & Surgical Hospitals, NEC; CIK 0000352915

C

middle fifth of 369 graded peers in healthcare

rank 199 of 369; percentile 53.8; sampling error 2.5 points; lower is stronger

A B C D E

C, the tortoise



Scoreboard	
Profitability	C percentile 55.5
Solvency	C percentile 47.5
Growth and financing	C percentile 44.6
Reliability	0.94 AUC filers with over $2.67B assets; 95% interval 0.88 to 0.97; 61 events, 2020 to 2025
Peer failure rate	0.52% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	over $2.67B assets total assets $15.5B
Standard universe	inside revenue above $1M and assets above $10M
Warnings	none triggered not computable: dilution, distress
Inputs computable	9 of 14
Graded from	filings received through Feb 25, 2026 248 days before the rescan; latest periodic filing 10-Q received Aug 7, 2026
Last close	$176.03 2026-10-30; market equity $0; no price enters the letter

Share price, twelve months to the rescan



Split-adjusted close. Each lollipop is a rescan and carries the letter held then.

Letter at every rescan, 2012 to 2026



Sector percentile at each rescan, stronger toward the top; facts filed by each date only.

Business, in the company's words

opening of Item 1 of the 10-K received Feb 25, 2026

Our principal business is owning and operating, through our subsidiaries, acute care hospitals and outpatient facilities and behavioral health care facilities. As of February 25, 2026, we owned and/or operated 375 inpatient facilities and 168 outpatient and other facilities located in 40 states, Washington, D.C., the United Kingdom and Puerto Rico. We have changed the method of our outpatient behavioral health care facility counts during the third quarter of 2025 and substantially all of the increase from prior periods is related to that change in convention.

The fourteen inputs

lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight

Input	Value	Peer median	Percentile, 0 to 100	Pct	Peers	Period end
Profitability, sleeve percentile 55.5						
Gross profitability	not computable	32.4%				
one or more required annual facts are missing						
Return on invested capital	13.3%	9.3%		37.0	74	2025-12-31

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Accruals ratio	(2.5%)	(6.6%)	74.1	803	2025-12-31
Gross margin stability, five years	not computable	2.8 pts			
five annual gross margins are required; found 0					
Solvency, sleeve percentile 47.5					
Twelve-month failure probability	not computable	0.07%			
liabilities and a nearby cover-page share count are required at 2026-06-30					
Altman Z double-prime	not computable	(0.35)			
one or more required annual facts are missing					
Net debt to EBITDA	1.78x	1.82x	48.6	75	2025-12-31
Interest coverage	12.78x	(4.51x)	5.2	78	2025-12-31
Current ratio	1.05x	2.92x	88.5	829	2025-12-31
Growth and financing, sleeve percentile 44.6					
Revenue growth, three-year compound	9.0%	10.1%	53.3	412	2025-12-31
Free cash flow growth, three-year compound	48.0%	10.9%	13.7	96	2025-12-31
Reinvestment rate	(1.1%)	37.1%	69.9	104	2025-12-31
Asset growth, three years	4.8%	2.2%	41.7	696	2025-12-31
Net share issuance, one year	not computable	2.5%			
two annual share counts are required; found 0					

Among 369 peers

healthcare; letters are fifths of this list



Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.

Rank	Company	Percentile	Letter	Warnings
194	Perrigo Co. plc (PRGO)	52.4	C	
195	Nexgel, Inc. (NXGL)	52.9	C	late filer
196	Nexgel, Inc. (NXGLW)	52.9	C	late filer
197	Aveanna Healthcare Holdings, Inc. (AVAH)	53.3	C	
198	Sotera Health Co. (SHC)	53.5	C	
199	Universal Health Services Inc. (UHS)	53.8	C	
200	Emergent BioSolutions Inc. (EBS)	54.1	C	
201	Teladoc Health, Inc. (TDOC)	54.3	C	fortress balance sheet
202	Roivant Sciences Ltd. (ROIV)	54.6	C	fortress balance sheet
203	Cabaletta Bio, Inc. (CABA)	54.9	C	dilution
204	Abbott Laboratories (ABT)	55.2	C	

What the price implies

at the 2026-10-30 close; none of these enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	(16.5%)	7.3%	33
Distance from 52-week high	(27.9%)	(28.7%)	52
EBIT to enterprise value	not computable	(1.4%)	
Free cash flow yield	not computable	(1.0%)	
Book value to price	not computable	0.28	

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Sales to price	not computable	0.30	
Composite equity issuance, five years	not computable	20.5%	
Relative strength against the sector, log excess return	(0.39)	(0.14)	33

Diagnostics

shown on every report; none enters the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	pass
Operating cash flow above zero	pass
Return on assets improved	pass
Operating cash flow exceeds net income	pass
Long-term leverage fell	pass
Current ratio improved	fail
No new shares issued	fail
Gross margin improved	fail
Asset turnover improved	pass
Cash, filings, liquidity	
Cash and equivalents	$138.8M
Operating cash flow, four quarters	$1.8B
Months of runway	not finite
Days since last periodic filing	85 (10-Q received Aug 7, 2026)
Median daily dollar volume, 63 sessions	$108.4M

Sources

every fact behind the inputs; each row links to its filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	operating income	us-gaap:OperatingIncomeLoss	$2.0B	2025-12-31	2026-02-25	10-K	26-071676
2	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeInc...	$2.0B	2025-12-31	2026-02-25	10-K	26-071676
3	income tax	us-gaap:IncomeTaxExpenseBenefit	$461.0M	2025-12-31	2026-02-25	10-K	26-071676
4	total debt	us-gaap:LongTermDebt	$4.8B	2025-12-31	2026-02-25	10-K	26-071676
5	book equity	us-gaap:StockholdersEquity	$7.3B	2025-12-31	2026-02-25	10-K	26-071676
6	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	$137.8M	2025-12-31	2026-02-25	10-K	26-071676
7	total debt	us-gaap:LongTermDebt	$4.5B	2024-12-31	2026-02-25	10-K	26-071676
8	book equity	us-gaap:StockholdersEquity	$6.7B	2024-12-31	2026-02-25	10-K	26-071676
9	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	$126.0M	2024-12-31	2026-02-25	10-K	26-071676
10	net income	us-gaap:NetIncomeLoss	$1.5B	2025-12-31	2026-02-25	10-K	26-071676
11	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$1.9B	2025-12-31	2026-02-25	10-K	26-071676
12	assets	us-gaap:Assets	$15.5B	2025-12-31	2026-02-25	10-K	26-071676
13	assets	us-gaap:Assets	$14.5B	2024-12-31	2026-02-25	10-K	26-071676
14	depreciation amortization	us-gaap:Depreciation	$594.0M	2025-12-31	2026-02-25	10-K	26-071676
15	interest expense	us-gaap:InterestExpense	$156.1M	2025-12-31	2026-02-25	10-K	26-071676
16	current assets	us-gaap:AssetsCurrent	$3.4B	2025-12-31	2026-02-25	10-K	26-071676
17	current liabilities	us-gaap:LiabilitiesCurrent	$3.2B	2025-12-31	2026-02-25	10-K	26-071676
18	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$17.4B	2025-12-31	2026-02-25	10-K	26-071676
19	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$15.8B	2024-12-31	2026-02-25	10-K	26-071676
20	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$14.3B	2023-12-31	2026-02-25	10-K	26-071676
21	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$13.4B	2022-12-31	2025-02-26	10-K	25-027785
22	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$1.0B	2025-12-31	2026-02-25	10-K	26-071676
23	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$2.1B	2024-12-31	2026-02-25	10-K	26-071676
24	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$943.8M	2024-12-31	2026-02-25	10-K	26-071676
25	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$1.3B	2023-12-31	2026-02-25	10-K	26-071676
26	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$743.1M	2023-12-31	2026-02-25	10-K	26-071676
27	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$996.0M	2022-12-31	2025-02-26	10-K	25-027785

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

28	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$734.0M	2022-12-31	2025-02-26	10-K	25-027785
29	current assets	us-gaap:AssetsCurrent	$2.8B	2024-12-31	2026-02-25	10-K	26-071676
30	current liabilities	us-gaap:LiabilitiesCurrent	$2.2B	2024-12-31	2026-02-25	10-K	26-071676
31	assets	us-gaap:Assets	$14.0B	2023-12-31	2025-02-26	10-K	25-027785
32	assets	us-gaap:Assets	$13.5B	2022-12-31	2024-02-27	10-K	24-021175

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.